Syntheses of 5-(2-radiohaloethyl)- and 5-(2-radiohalovinyl)-2′- deoxyuridines. Novel types of radiotracer for monitoring cancer gene therapy with PET
✍ Scribed by Chung-Shan Yu; Joseph Eisenbarth; Armin Runz; Klaus Weber; Stephan Zeisler; Franz Oberdorfer
- Book ID
- 102373207
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- French
- Weight
- 197 KB
- Volume
- 46
- Category
- Article
- ISSN
- 0022-2135
- DOI
- 10.1002/jlcr.684
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Syntheses of 5‐(2‐[^18^F]fluoroethyl)‐ (1), 5‐(2‐[^80^Br]bromoethyl)‐ (2), un‐deprotected (E)‐5‐(2‐[^18^F]fluorovinyl)‐ (3) and (E)‐5‐(2‐[^80^Br]bromovinyl)‐2′‐deoxyuridines (4) as the tracers for monitoring cancer gene therapy with positron emission tomography were described. Decay corrected radiochemical yield and synthesis time including labeling and HPLC purification from end of bombardment for 1 was 9.5% and 2 hours, respectively; yield and time for 2 was 16% and 2 hours, respectively. Chemical (approximate to radiochemical) yield and time for synthesis of 3 was 7.5% and 7 minutes, respectively. Radiochemical yield and synthesis time including labeling and HPLC purification of an analytical sample of 4 was 60% and 30 minutes, respectively. Both 2 and 4 received the side reactions during HPLC purification, i.e. ring closure and cleavage of glycosidic bond, respectively. Application of 2 and 4 needed to be confirmed by in vitro or in vivo experiments. Radiochemical yield of 1 could be optimized by employing a modified protocol for preparation of its precursor. The preparation of fluorovinyl counterparts had demonstrated the potential utility of the stannane, 3‐tolyl‐3′,5′‐di‐O‐acetyl‐(E)‐5‐(2‐stannylvinyl)‐2′‐deoxyuridine 7. Copyright © 2003 John Wiley & Sons, Ltd.